Hepa 1-6 除外且通过Anti- PD-1 治疗显示出最大程度的肿瘤缩小(图 4D)。总体而言,这些结果与之前的免疫学特征定义相吻合。 图4 抗 PD-1 疗法的体内疗效在肝细胞癌细胞系模型中存在差异 5.HCC的同基因小鼠模型反映了人类HCC的独特亚...
The efficacy was compared between groups after propensity-score matching.There were 173 HCC patients receiving anti-PD-1. After excluding unsuitable cases, 140 patients were analyzed, of which 58 received combination therapy and 82 received anti-PD-1 alone. The combination therapy had a trend of ...
CRKL/β-catenin/VEGFα和CXCL1轴的激活是成功抗PD-1治疗的关键障碍。因此，CRKL抑制剂联合抗PD-1可能用于治疗HCC。肝细胞癌(HCC)是全球癌症相关死亡的第三大原因。虽然HCC治疗有了很大的进步，但大多数HCC患者不符合手术切除标准。免疫检查点抑制剂(ICIs)在癌症免疫治疗领域取得了不可磨灭的成就;根据III期临床试验...
近日,复旦大学附属中山医院肝癌研究所柯爱武、蔡加彬、施国明等合作在Molecular Cancer杂志(IF=15.302)发表文章,报道了癌细胞分泌的外泌体中富含环状RNA——circUHRF1,circUHRF1通过抑制miR-449c-5p,来上调TIM-3的表达,从而抑制NK细胞功能,诱导NK细胞衰竭,并可能对肝细胞癌的抗PD1治疗产生抗药性。 肝细胞癌(HCC)...
Despite remarkable advancements in cancer immunotherapy, the overall response rate to anti-programmed cell death-1 (anti-PD-1) therapy in hepatocellular carcinoma (HCC) patients remains low. Our previous study has demonstrated the critical role of CacyBP/SIP (Calcyclin-Binding Protein and Siah-1 In...
Immune check point antibodies, such as anti-PD1, anti-PD-L1, anti-CTLA4 have led to breakthroughs for the treatment of many tumor types; However, tumor types such as HCC, pancreatic and colon cancers have had relatively low response rates to these antibodies. Currently hundreds of remedies ...
为10例已知anti-PD-1单药治疗有效性的肝细胞癌晚期患者的特征向量R N (N=1,2,3,...,10)。 说明书 技术领域 本发明涉及药物治疗有效性评估技术领域,具体涉及一种基于外周血免疫细胞图谱的anti-PD-1单药治疗有效性评估系统。 背景技术 肝细胞癌(Hepatocellular carcinoma,HCC)是原发性肝癌中最常见的病理类型...
Hepatocellular carcinoma (HCC) is one of the commonest lethal malignancies worldwide, and often diagnosed at an advanced stage, without any curative therapy. Immune checkpoint blockers targeting the programmed death receptor 1 (PD-1) have shown impressive antitumor activity in patients with advanced-...
Patients were randomly assigned to receive pembrolizumab (anti-PD-1 antibody) or placebo plus best supportive care. Notably, this trial stands as the first and potentially exclusive phase III study to establish the efficacy of ICB monotherapy in advanced HCC by demonstrating significant improvements ...
Anti-programmed cell death protein 1 (PD-1) therapy has shown promising efficacy in hepatocellular carcinoma (HCC), but its response rates in advanced HCC are lower than 20%. A critical reason for this is the imbalance between CD8+ T cells and tumor burden. Here, a novel concept of vascul...